BenzingaAugust 14, 2026 at 10:23 AM NY21 days ago

B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story